Resources

In part 5 of this Exclusive Interview, John Buse talks with Diabetes in Control Publisher Steve Freed about studies on the use of SGLT in other populations — people without diabetes, people with kidney disease, etc.

In part 6 of this Exclusive Interview, John Buse compares the Observe 4D study to other similar studies in a conversation with Diabetes in Control Publisher Steve Freed.

In part 7 of this Exclusive Interview, John Buse urges other medical professionals to weigh the risks and benefits of using SGLT in a conversation with Diabetes in Control Publisher Steve Freed.

In part 8, the conclusion of this Exclusive Interview, John Buse talks with Diabetes in Control Publisher Steve Freed about the good and bad effects of using SGLT2 for patients who have type 1.

Researchers find increased risk in people with type 1 who have glucose levels greater than 8.0%.

More accurate genes to screen for type 1 diabetes in both newborns and adults identified.

Is it true that individuals paying for diabetes care and management using fee-for-service clinics may have better outcomes in their glucose levels?

People with diabetes can benefit from a lower portion of carbohydrates in their diet, but this adjustment may lead to other risks.

Can sitting for just 3 hours non-stop at one time hurt the heart?

Based on a meta-analysis of cardiovascular outcomes in type 2 diabetes studies, the findings suggest that a 15% relative risk reduction in nonfatal myocardial infarcts is associated with an A1c reduction of approximately:

A. .50%
B. 1.0%
C. 1.5%
D. 2.0%

Follow the link for the answer.